Deals Of The Week: Sanofi/Micromet, Cephalon/BioAssets, GSK/SuperGen...
Executive Summary
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.
You may also be interested in...
Micromet Gets $12M Upfront From Sanofi For Discovery-Stage Oncology Antibody
This is Sanofi-Aventis' third oncology partnership this year, as it continues to seek new cancer drugs to replace Taxotere and Eloxatin.
PPD To Spin Out Compound Partnering Unit And Invest In Celtic Pharmaceutical
The CRO looks to remake itself and invest $100 million in Celtic Pharmaceutical Holdings, which wants mid-stage development projects.
Glaxo And SuperGen Team Up In An Option Deal For Cancer Targets
GlaxoSmithKline will pay $5 million upfront for an option to develop cancer drugs based on epigenetic targets; deal is GSK's sixth option-alliance this year.